

Multiple drugs

S

Lack of efficacy and off label use: case report

A 61-year-old-man exhibited lack of efficacy while receiving ciprofloxacin, dexamethasone, nitric oxide and meropenem for acute respiratory distress syndrome (ARDS). Additionally, he received off label treatment with dexamethasone and interferon gamma for COVID-19 [not all routes and dosages stated].

The man was diagnosed COVID-19, and was admitted to ICU on day 12 after first symptoms with worsening condition. He had two-level ventilation with unspecified neuromuscular blockade and nitric oxide. Thereafter, he received off-label IV dexamethasone 6mg per day for 10 days. Subsequently, a diagnosis of superinfected COVID-19 ARDS was confirmed. He was firstly treated with piperacillin/tazobactam for 6 days. Antibiotic treatment was changed to meropenem and ciprofloxacin following detection of a resistant *Pseudomonas aeruginosa* and a non-resistant *Klebsiella oxytoca*. Due to the stagnant clinical status following 16 days in ICU, he received off label treatment with SC interferon gamma [interferon- γ] 100 μ g on day 28 to reduce the acquired immunosuppression. Additionally, he received norepinephrine concomitantly. However, 29 days following the first symptom of COVID-19, he died from refractory ARDS.

Dickel S, et al. Case Report: Interferon-gamma Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome. *Frontiers in Immunology* 12: 7 Apr 2021. Available from: URL: <https://www.frontiersin.org/journals/immunology/>

803616435